Clinical Trials Browser

Phase 3 × Advanced Non-squamous Non-small-cell Lung Cancer × tislelizumab × Clear all

NCT06416410 2025-04-04

JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation

Phase 3 Recruiting

Advanced Non-squamous Non-small-cell Lung Cancer